Stocktoria
PharmaCyte Biotech, Inc. PMCB
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2003-09-11
PharmaCyte Biotech, Inc. financials (annual)
Bars are annual figures from 2017 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $391,301 | $438,416 | $407,431 | $468,536 | $690,937 | $916,249 | $301,221 | $460,052 | $2.0M | $1.2M |
| Operating income | -$6.9M | -$4.4M | -$8.5M | -$6.5M | -$4.4M | -$3.6M | -$3.8M | -$4.1M | -$7.0M | -$4.4M |
| Interest expense | — | — | — | $0 | $509 | $3,046 | $453 | $0 | $0 | $1,539 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$19.4M | $30.7M | $333,763 | -$4.3M | -$4.2M | -$3.6M | -$3.8M | -$4.1M | -$6.8M | -$4.4M |
| EPS (diluted) | $-2.77 | $3.19 | $-1.80 | $-0.22 | $-0.27 | $-2.45 | — | — | — | — |
| Operating cash flow | -$5.2M | -$3.0M | -$2.2M | -$3.8M | -$4.1M | -$3.3M | -$2.3M | -$2.9M | -$5.1M | -$3.3M |
| Cash & equivalents | $18.6M | $15.2M | $50.2M | $68.0M | $85.4M | — | — | — | — | — |
| Total assets | $46.8M | $55.2M | $59.9M | $73.3M | $90.6M | $7.4M | $6.2M | $5.8M | $6.4M | $8.7M |
| Total liabilities | $11.8M | $3.3M | $20.4M | $586,581 | $704,370 | $724,778 | $1.1M | $742,851 | $644,168 | $580,248 |
| Shareholders' equity | $33.3M | $51.9M | $27.6M | $72.7M | $89.9M | $6.7M | $5.1M | $5.0M | $5.8M | $8.1M |
Growth · year-over-year
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income growth | -163.4% | +9085.0% | — | — | — | — | — | — | — | — |
| EPS growth | -186.8% | — | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-04-30. Facts plus Stocktoria's own computed scores — not investment advice.